Schlenker provided guidance for the fourth quarter, stating, "We expect revenues before reimbursements to grow in the low to mid-single digits, EBITDA to be 26% to 27% of revenues before ...
Exponent (EXPO) has been quietly grinding higher, with the stock up roughly 4% over the past month and 5% in the past 3 months, even as its one year return remains negative. See our latest analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback